<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: should carefully", fill: "#9b111e"},
{source: "1: should carefully", target: "1: following risks", fill: "#9b111e"},
{source: "1: following risks", target: "1: common stock", fill: "#9b111e"},
{source: "1: should carefully", target: "3: Additional ", fill: "#c72c48"},
{source: "3: Additional ", target: "3: presently known", fill: "#c72c48"},
{source: "3: presently known", target: "3: immaterial may also impair", fill: "#c72c48"},
{source: "3: immaterial may also impair", target: "3: operations", fill: "#c72c48"},
{source: "3: Additional ", target: "6: unsuccessful", fill: "#800000"},
{source: "6: unsuccessful", target: "6: approval from", fill: "#800000"},
{source: "6: approval from", target: "6: commercialize", fill: "#800000"},
{source: "6: commercialize", target: "6: Genasense ", fill: "#800000"},
{source: "6: Genasense ", target: "6: pharmaceutical", fill: "#800000"},
{source: "6: unsuccessful", target: "7: commercialization", fill: "#d3d3d3"},
{source: "7: commercialization", target: "7: pharmaceutical products involves", fill: "#d3d3d3"},
{source: "7: pharmaceutical products involves", target: "7: significant challenges", fill: "#d3d3d3"},
{source: "7: commercialization", target: "8: commercialize", fill: "#e4d00a"},
{source: "8: commercialize", target: "8: products such as", fill: "#e4d00a"},
{source: "8: products such as", target: "8: Ganite and Genasense ", fill: "#e4d00a"},
{source: "8: Ganite and Genasense ", target: "8: clinical development programs", fill: "#e4d00a"},
{source: "8: clinical development programs", target: "8: regulatory", fill: "#e4d00a"},
{source: "8: regulatory", target: "8: marketing efforts directed at", fill: "#e4d00a"},
{source: "8: marketing efforts directed at", target: "8: physicians patients", fill: "#e4d00a"},
{source: "8: physicians patients", target: "8: thirdparty payors", fill: "#e4d00a"},
{source: "8: commercialize", target: "53: future capital requirements will depend on", fill: "#ffe5b4"},
{source: "53: future capital requirements will depend on", target: "53: development activities preclinical studies", fill: "#ffe5b4"},
{source: "53: development activities preclinical studies", target: "53: clinical trials competitive", fill: "#ffe5b4"},
{source: "53: clinical trials competitive", target: "53: technological advances", fill: "#ffe5b4"},
{source: "53: technological advances", target: "53: regulatory activities", fill: "#ffe5b4"},
{source: "53: regulatory activities", target: "53: regulatory authorities", fill: "#ffe5b4"},
{source: "53: future capital requirements will depend on", target: "73: Aventis Pharmaceuticals Inc ", fill: "#cf0"},
{source: "73: Aventis Pharmaceuticals Inc ", target: "73: Group or Aventis ", fill: "#cf0"},
{source: "73: Group or Aventis ", target: "73: agreement", fill: "#cf0"},
{source: "73: agreement", target: "73: development", fill: "#cf0"},
{source: "73: development", target: "73: commercialization collaboration", fill: "#cf0"},
{source: "73: Aventis Pharmaceuticals Inc ", target: "START_HERE", fill: "#cf0"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Oblimersen">Oblimersen</a></td>
      <td>Oblimersen (INN, trade name Genasense; also known as Augmerosen and bcl-2 antisense oligodeoxynucleotide G3139) is an antisense oligodeoxyribonucleotide being studied as a possible treatment for several types of cancer, including chronic lymphocytic leukemia, B-cell lymphoma, and breast cancer. It may kill cancer cells by blocking the production of Bcl-2—a protein that makes cancer cells live longer—and by making them more sensitive to chemotherapy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genta_(company)">Genta (company)</a></td>
      <td>Genta Incorporated was a biopharmaceutical company started in La Jolla, California, which discovered and developed innovative drugs for the treatment of patients with cancer. Founded in 1989 by a highly skilled entrepreneur, the company focused on a novel technology known as antisense, which targets gene products that are associated with the onset and progression of serious diseases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Germinal_center_B-cell_like_diffuse_large_B-cell_lymphoma">Germinal center B-cell like diffuse large B-cell lymphoma</a></td>
      <td>Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at ~70 years, although it can occur in young adults and, in rare cases, children.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GENTA INC DE/      Item 1A Risk Factors            You <font color="blue">should carefully</font> consider the <font color="blue">following risks</font> and all of the other     information set forth in this Form 10K before deciding to invest in shares     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are not the <font color="blue">only ones facing</font>     our Company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">presently known</font> to us or that we currently     deem <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks</font> actually occurs, our business, financial     condition or results of <font color="blue">operations</font> <font color="blue">would likely</font> suffer</td>
    </tr>
    <tr>
      <td>In such case, the     <font color="blue">market price</font> of our <font color="blue">common stock</font> <font color="blue">would likely</font> decline due to the occurrence     of any of these risks, and you may lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________           Risks Related to Our Business           We may be <font color="blue">unsuccessful</font> in our efforts to obtain <font color="blue">approval from</font> the FDA or     EMEA and <font color="blue">commercialize</font> Genasense® or our other <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercialization</font> of our <font color="blue">pharmaceutical</font> products involves a number     of <font color="blue"><font color="blue">significant</font> challenges</font></td>
    </tr>
    <tr>
      <td>In particular, our ability to <font color="blue">commercialize</font>     products, such as Ganite® and Genasense®, depends, in large part, on the     success  of  our  <font color="blue">clinical <font color="blue">development</font> programs</font>, our efforts to obtain     <font color="blue">regulatory</font>  approvals  and our sales and <font color="blue">marketing efforts directed at</font>     physicians, patients and third-party payors</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors could</font>     affect these efforts, including:       o   our ability to <font color="blue"><font color="blue">demonstrate</font> clinically</font> that our products are useful and     safe in <font color="blue">particular <font color="blue"><font color="blue">indication</font>s</font></font>;       o   delays or refusals by <font color="blue">regulatory</font> <font color="blue">authorities</font> in <font color="blue">granting marketing</font>     approvals;       o   our limited <font color="blue">financial resources</font> and sales and marketing experience     relative to our <font color="blue">competitors</font>;       o   actual and perceived <font color="blue">differences between</font> our products and those of our     <font color="blue">competitors</font>;       o   the <font color="blue">availability</font> and level of <font color="blue">reimbursement</font> for our <font color="blue">products by</font>     third-party payors;       o   <font color="blue">incidents</font> of <font color="blue">adverse reactions</font> to our products;       o   side effects or misuse of our products and the <font color="blue">unfavorable publicity</font>     that could result; and       o   the occurrence of manufacturing, supply or <font color="blue"><font color="blue">distribution</font> disruptions</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that Genasense® will receive <font color="blue">FDA or EMEA </font>approval</td>
    </tr>
    <tr>
      <td>Our  financial  condition and results of <font color="blue">operations</font> have been and will     continue to be <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> affected by</font> <font color="blue">FDA and EMEA </font><font color="blue">action with respect</font> to     Genasense®</td>
    </tr>
    <tr>
      <td>Any <font color="blue">adverse events with respect</font> to FDA and/or EMEA approvals     <font color="blue">could <font color="blue">negatively impact</font></font> our ability to obtain <font color="blue"><font color="blue">additional</font> funding</font> or identify     <font color="blue">potential partners</font></td>
    </tr>
    <tr>
      <td>For example, on January 3, 2006, we announced that we had completed a     Marketing Authorization Application, or MAA, to <font color="blue">the EMEA </font>that <font color="blue">seeks approval</font>     for use of Genasense® <font color="blue">plus dacarbazine</font> for the treatment of <font color="blue">patients with</font>     <font color="blue">advanced melanoma</font> who have not <font color="blue">previously</font> received <font color="blue">chemotherapy</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">On <font color="blue">February </font></font>    </font>1, 2006, we announced that we had received notice from <font color="blue">the EMEA </font>that our MAA     was validated for review by <font color="blue">the EMEA </font>We anticipate receiving <font color="blue">consolidated</font>     <font color="blue">questions from</font> <font color="blue">the EMEA </font>approximately 120 days from the date of the MAA’s     <font color="blue">validation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">centralized licensing procedure provides</font> a <font color="blue">single marketing</font>     <font color="blue">authorization</font>  that  is  valid in all 25-member states of the European     Community</td>
    </tr>
    <tr>
      <td>Review of the <font color="blue">application</font> is <font color="blue">coordinated by</font> the EMEA, and Spain     and France have <font color="blue">been appointed as rapporteur</font> and co-rapporteur countries,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">December </font></font>28, 2005, we completed submission of an <font color="blue">NDA <font color="blue">to the FDA </font></font>that     <font color="blue">sought accelerated approval</font> for the use of Genasense® in <font color="blue">combination</font> with     fludarabine  plus  <font color="blue">cyclophosphamide</font> for the treatment of <font color="blue">patients with</font>     relapsed  or  <font color="blue">refractory</font> CLL who have <font color="blue">previously</font> received fludarabine</td>
    </tr>
    <tr>
      <td>Genasense® has received <font color="blue">Fast Track </font><font color="blue"><font color="blue">designation</font> by</font> the FDA in CLL, meaning     that the <font color="blue"><font color="blue">indication</font> represents</font> an unmet medical need</td>
    </tr>
    <tr>
      <td>Genasense® has also     <font color="blue">been granted <font color="blue">designation</font> as</font> an <font color="blue">Orphan Drug </font>by the FDA On March 1, 2006, we     announced that the NDA had <font color="blue">been accepted</font> for review by the FDA with a target     <font color="blue">action date</font> of October 28, 2006</td>
    </tr>
    <tr>
      <td>However, <font color="blue">acceptance</font> of this NDA does not     <font color="blue">necessarily lead</font> to FDA approval</td>
    </tr>
    <tr>
      <td>After reviewing in May 2005 a summary of     our <font color="blue"><font color="blue">preliminary</font> clinical data</font> that were released in November 2004 from our     CLL trial, the FDA expressed concern that simply achieving statistical     significance  in  the  <font color="blue">primary endpoint</font> (complete <font color="blue">plus nodular partial</font>     responses [CR/nPR]) may not be likely to convey or <font color="blue">predict <font color="blue">clinical benefit</font></font>,     <font color="blue">particularly</font>  <font color="blue">absent <font color="blue">improvement</font></font> in time-to-progression</td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent </font>to     <font color="blue">preparation</font> of the <font color="blue"><font color="blue">preliminary</font> data summary</font>, the Company <font color="blue">compiled <font color="blue">additional</font></font>     information to support its claims of <font color="blue">clinical benefit</font></td>
    </tr>
    <tr>
      <td>First, the proportion     of patients who relapsed from CR/nPR increased <font color="blue">substantially</font> over time from     25prca  to  75prca  in the patient group treated with <font color="blue">chemotherapy</font> alone</td>
    </tr>
    <tr>
      <td>By     contrast, the <font color="blue">comparable increase</font> in the Genasense® group was 16prca to 25prca,     <font color="blue">which indicated</font> a <font color="blue">lower risk</font> of relapse</td>
    </tr>
    <tr>
      <td>Second, the <font color="blue">preliminary</font> clinical     data indicated that the median duration of CR/nPR had not <font color="blue">been reached</font> in     <font color="blue">either treatment</font> group</td>
    </tr>
    <tr>
      <td>Further follow-up showed that CR/nPRs achieved with     the addition of Genasense® to <font color="blue">chemotherapy</font> were <font color="blue"><font color="blue">significant</font>ly</font> longer when     compared with those responses achieved with <font color="blue">chemotherapy</font> alone</td>
    </tr>
    <tr>
      <td>For example,     the median CR/nPR duration in the <font color="blue">chemotherapy</font> alone group was reached at 22     months, whereas the median has still not <font color="blue">been reached</font> in the Genasense®     group  [P=0dtta03]</td>
    </tr>
    <tr>
      <td>Third,  the Company had <font color="blue">prospectively collected data</font>     regarding <font color="blue">specific parameters</font> of disease-related morbidity, including but     not limited to symptoms</td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent </font>analysis of these <font color="blue">data showed</font> that     patients in the Genasense® treatment group who achieved CR/nPR <font color="blue">also attained</font>     substantial  <font color="blue">improvement</font> in these <font color="blue">disease parameters</font></td>
    </tr>
    <tr>
      <td>The NDA that was     <font color="blue">submitted by</font> the <font color="blue">Company in <font color="blue">December </font></font>2005, which includes these data, was     <font color="blue">subsequently accepted</font> for review by the <font color="blue">FDA in <font color="blue">February </font></font>2006</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________            <font color="blue">Following </font>its review of all our information <font color="blue">concerning</font> Genasense®, the     FDA  may  refuse to <font color="blue">approve altogether</font>, or may ask for more data to be     obtained, so that approval can be <font color="blue">reconsidered</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">decisions</font> by     the  FDA  would  have  a  material adverse effect on our business</td>
    </tr>
    <tr>
      <td>One     <font color="blue">requirement</font> for <font color="blue">Accelerated Approval </font>is that we will be required to conduct     a <font color="blue">confirmatory trial</font></td>
    </tr>
    <tr>
      <td>We have formulated a design for such a trial and have     submitted a proposal <font color="blue">to the FDA </font>for review as a Special Protocol Assessment,     or SPA The <font color="blue">submitted proposal incorporated initial comments</font> received from     the FDA Final <font color="blue">comments on</font> the submission are expected during the first half     of 2006</td>
    </tr>
    <tr>
      <td>Formal <font color="blue">initiation</font> of the trial will depend upon resolution of trial     design  issues  with the FDA, among other factors</td>
    </tr>
    <tr>
      <td>Although <font color="blue">Fast Track </font>    <font color="blue">designation</font>, <font color="blue">Orphan Drug </font><font color="blue">designation</font> and <font color="blue">Accelerated Approval </font>provisions are     beneficial,  we  cannot  assure  you that the NDA will be approved</td>
    </tr>
    <tr>
      <td>In     particular, the FDA may not be satisfied that <font color="blue">achievement</font> of the primary     endpoint  used  in  our  recent <font color="blue">clinical trial</font>, which was an increased     proportion of complete responses/nodular partial responses compared to     <font color="blue">patients treated with</font> standard <font color="blue">chemotherapy</font>, is a <font color="blue">sufficient basis</font> for     approval</td>
    </tr>
    <tr>
      <td>Further, increased symptom-free time may not be considered to be     <font color="blue">sufficient demonstration</font> of <font color="blue">clinical benefit</font></td>
    </tr>
    <tr>
      <td>Ultimately, our <font color="blue">efforts may</font> not prove to be <font color="blue">as <font color="blue">effective</font> as</font> those of     our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">In the <font color="blue">United States</font> </font>and elsewhere, our <font color="blue">products will</font> face     <font color="blue">significant</font> <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">principal conditions on which</font> our product     <font color="blue"><font color="blue">development</font> efforts</font> are focused and some of the other disorders for which we     are <font color="blue">conducting <font color="blue">additional</font> studies</font>, are <font color="blue">currently treated with several drugs</font>,     many of which have <font color="blue">been available</font> for a number of years or are available in     <font color="blue">inexpensive generic forms</font></td>
    </tr>
    <tr>
      <td>Thus, even if we obtain <font color="blue">regulatory</font> approvals, we     will need to <font color="blue">demonstrate</font> to physicians, patients and third-party payors that     the cost of our products is reasonable and <font color="blue">appropriate</font> in light of their     safety and efficacy, the price of <font color="blue">competing products</font> and the <font color="blue">relative health</font>     <font color="blue">care benefits</font> to the patient</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">demonstrate</font> that the costs     of our products are reasonable and <font color="blue">appropriate</font> in light of these factors, we     <font color="blue">will likely</font> be <font color="blue">unsuccessful</font> in <font color="blue">commercializing</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">Recurring </font>losses and <font color="blue">negative cash flows from</font> <font color="blue">operations</font> raise substantial     <font color="blue">doubt about</font> our ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>Our recurring losses from <font color="blue">operations</font> and <font color="blue">negative cash flows from</font>     <font color="blue">operations</font> raise substantial <font color="blue">doubt about</font> our ability to <font color="blue">continue as</font> a going     concern and as a result, our <font color="blue">independent registered public accounting firm</font>     included  an  <font color="blue">explanatory</font>  paragraph in its report on our <font color="blue">consolidated</font>     <font color="blue">financial statement</font> for the year ended <font color="blue">December </font>31, 2005 with respect to     this <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantial </font><font color="blue">doubt about</font> our ability to <font color="blue">continue as</font> a going     concern may create <font color="blue">negative reactions</font> to the price of the <font color="blue">common shares</font> of     our stock and we may have a more <font color="blue">difficult</font> time obtaining financing</td>
    </tr>
    <tr>
      <td>We have prepared our <font color="blue">financial statement</font>s on a going concern basis,     which  contemplates  the <font color="blue">realization</font> of assets and the <font color="blue">satisfaction</font> of     <font color="blue">liabilities</font> and <font color="blue">commitments</font> in the <font color="blue">normal course</font> of business</td>
    </tr>
    <tr>
      <td>The financial     statements do not include any <font color="blue">adjustments</font> relating to the <font color="blue">recoverability</font> and     classification of <font color="blue">recorded asset amounts</font> or amounts of <font color="blue">liabilities</font> that     might be <font color="blue"><font color="blue">necessary</font> should</font> we be unable to continue in existence</td>
    </tr>
    <tr>
      <td>Our business will suffer if we fail to obtain <font color="blue">timely funding</font></td>
    </tr>
    <tr>
      <td>We may be     unable to <font color="blue">raise <font color="blue">additional</font> capital</font> when needed and may not <font color="blue">continue as</font> a     going concern</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have required <font color="blue">significant</font> cash expenditures</td>
    </tr>
    <tr>
      <td>As     a result of Aventis’ <font color="blue">termination</font> <font color="blue">of the Collaborative Agreement</font>, after May     8, 2005, we <font color="blue">became <font color="blue">solely responsible</font></font> for all Genasense® related costs</td>
    </tr>
    <tr>
      <td>Our     future capital <font color="blue">requirement</font>s <font color="blue">will depend on</font> the results of our research and     <font color="blue">development</font> <font color="blue">activities</font>, <font color="blue">preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>, competitive     and <font color="blue">technological advances</font>, and <font color="blue">regulatory</font> <font color="blue">activities</font> of the FDA and other     <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">commercialize</font> our products, we will need     to <font color="blue">raise <font color="blue">additional</font> funds</font></td>
    </tr>
    <tr>
      <td>On August 11, 2005, we sold 19dtta1 million shares     of <font color="blue">common stock</font> at a price of dlra0dtta92 per share, raising dlra16dtta0 million, net of     fees and expenses</td>
    </tr>
    <tr>
      <td>In addition, on March 6, 2006, we executed <font color="blue">definitive</font>     subscription <font color="blue">agreement</font>s with institutional investors to sell 19 million     shares  of  our  common  stock  at  a price of dlra2dtta15 per share raising     approximately dlra37dtta8 million, net of estimated fees and expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Assuming     </font>the <font color="blue">completion</font> of this financing, <font color="blue">management</font> believes that at the projected     rate  of spending, including building our sales and marketing team and     <font color="blue">capabilities</font>, we should have sufficient cash funds to maintain our present     <font color="blue">operations</font> into the first quarter of 2007</td>
    </tr>
    <tr>
      <td>We will need to obtain more     funding in the <font color="blue">future through <font color="blue"><font color="blue">collaboration</font>s</font></font> or other <font color="blue"><font color="blue">arrangements</font> with</font>     <font color="blue">research <font color="blue">institutions</font></font> and <font color="blue">corporate partners</font> or public and <font color="blue">private offerings</font>     of our securities, including debt or <font color="blue">equity financing</font></td>
    </tr>
    <tr>
      <td>We may not be able to     obtain <font color="blue">adequate funds</font> for our <font color="blue">operations</font> from these sources when needed or     on acceptable terms</td>
    </tr>
    <tr>
      <td>Future <font color="blue"><font color="blue">collaboration</font>s</font> or similar <font color="blue"><font color="blue">arrangements</font> may</font>     require  us  to license valuable <font color="blue">intellectual property</font> to, or to share     substantial  economic  benefits  with,  our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>If we raise     <font color="blue"><font color="blue">additional</font> capital by issuing <font color="blue">additional</font> equity</font> or <font color="blue">securities convertible</font>     <font color="blue">into equity</font>, our <font color="blue"><font color="blue">stockholders</font> may</font> experience dilution and our share price     may decline</td>
    </tr>
    <tr>
      <td>Any <font color="blue">debt financing may</font> result in <font color="blue"><font color="blue">restrictions</font> on</font> our spending</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________            If we are unable to <font color="blue">raise <font color="blue">additional</font> funds</font>, we will need to do one or     more of the following:           o delay, scale back or eliminate some or all of our research and product     <font color="blue">development</font> programs;           <font color="blue">o license <font color="blue">third parties</font></font> to develop and <font color="blue">commercialize</font> products or     <font color="blue">technologies</font> that we <font color="blue">would otherwise seek</font> to develop and <font color="blue">commercialize</font>     ourselves;           o attempt to sell our company;           o cease <font color="blue">operations</font>; or           o declare <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>We intend to be a <font color="blue">direct marketer</font> of some products in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">effort will consume</font> large amounts of our resources and <font color="blue">management</font> time     and we may not be successful in our efforts</td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>we do not have a <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales force</font> was eliminated     in 2004 following our decision to withdraw the NDA <font color="blue">for Genasense</font>® for the     treatment of <font color="blue">advanced melanoma</font></td>
    </tr>
    <tr>
      <td>We intend to build a <font color="blue">sales force</font> throughout     the second and <font color="blue">third quarters</font> of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2006, we announced that we     had appointed <font color="blue">W Lloyd Sanders </font>as Vice-President of Sales and Marketing</td>
    </tr>
    <tr>
      <td><font color="blue">Sanders  </font>was  Vice President, Oncology Sales, at     sanofi-aventis Group</td>
    </tr>
    <tr>
      <td>If we are unable to build a <font color="blue">sales force</font> capable of     marketing  our products, our <font color="blue">sales will</font> be <font color="blue"><font color="blue">adversely</font> affected</font>, and the     <font color="blue">commercial success</font> of our <font color="blue">products will</font> be limited</td>
    </tr>
    <tr>
      <td>On May 10, 2005, we announced that we and Aventis Pharmaceuticals Inc, part     of sanofi-aventis Group, or Aventis, had signed an <font color="blue">agreement</font> to terminate     their <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">collaboration</font> <font color="blue">for Genasense</font>®</td>
    </tr>
    <tr>
      <td>We     lost a <font color="blue">significant</font> source of funding <font color="blue">for Genasense</font>® as a result of this     <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>In April 2002, we <font color="blue">entered into</font> a series of <font color="blue">agreement</font>s relating to the     <font color="blue">development</font>  and  <font color="blue">commercialization</font>  of  Genasense®, to which we refer     <font color="blue">collectively</font>  as  the  Collaborative  Agreement,  with Aventis and its     <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td><font color="blue">On November </font>8, 2004, we received from Aventis a notice of     <font color="blue">termination</font> <font color="blue">of the Collaborative Agreement</font></td>
    </tr>
    <tr>
      <td>On May 10, 2005, we announced     that we had signed an <font color="blue">agreement</font> with Aventis to terminate our <font color="blue">development</font>     and  <font color="blue">commercialization</font>  <font color="blue">collaboration</font>  <font color="blue">for Genasense</font>®</td>
    </tr>
    <tr>
      <td>The <font color="blue">termination</font>     <font color="blue">agreement</font> provided for no future financial <font color="blue">obligations</font> by either party</td>
    </tr>
    <tr>
      <td>Aventis <font color="blue">also returned</font> its <font color="blue">then current inventory</font> of Genasense® <font color="blue">drug supply</font>     to us</td>
    </tr>
    <tr>
      <td>In addition, we assumed <font color="blue">responsibility</font> for the <font color="blue">randomized clinical</font>     trial   of   Genasense®  in  <font color="blue">combination</font>  with  docetaxel  (Taxotere®;     sanofi-aventis) in <font color="blue">patients with</font> hormone-<font color="blue">refractory</font> prostate cancer, which     recently completed accrual</td>
    </tr>
    <tr>
      <td>Among other provisions, <font color="blue">the Standstill </font>and     Voting Agreement and Registration Rights Agreement that were established     pursuant to the Aventis <font color="blue">investment</font> in our <font color="blue">common stock</font> in 2002 did not     <font color="blue">terminate at</font> this time</td>
    </tr>
    <tr>
      <td>We are seeking a new partner for the <font color="blue">development</font> and <font color="blue">commercialization</font> of     Genasense®, and if we are unable to do so, we may not have sufficient     resources to fully develop and <font color="blue">commercialize</font> Genasense®</td>
    </tr>
    <tr>
      <td>If we are unable to identify a partner, we will be <font color="blue">solely responsible</font>     for the <font color="blue">development</font> and <font color="blue">commercialization</font> of Genasense®, including the costs     <font color="blue">associated therewith</font></td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient resources</font> to do so</td>
    </tr>
    <tr>
      <td>Even if     we are able to identify a partner, we may not be able to <font color="blue">enter into</font> an     <font color="blue">agreement</font> on acceptable terms or at all</td>
    </tr>
    <tr>
      <td>We have relied on and continue to rely on our <font color="blue">contractual <font color="blue">collaborative</font></font>     <font color="blue"><font color="blue">arrangements</font> with</font> <font color="blue">research <font color="blue">institutions</font></font> and <font color="blue">corporate partners</font> for     <font color="blue">development</font> and <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">could suffer</font>     if we are not able to <font color="blue">enter into</font> suitable <font color="blue">arrangements</font>, maintain existing     <font color="blue"><font color="blue">relationship</font>s</font>, or if our <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font> are not successful in     developing and <font color="blue">commercializing</font> products</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">entered into</font> <font color="blue">collaborative</font> <font color="blue"><font color="blue">relationship</font>s</font> relating to the     conduct of <font color="blue">clinical research</font> and other <font color="blue">research <font color="blue">activities</font></font> in order to     augment  our  internal  research  <font color="blue">capabilities</font> and to obtain access to     <font color="blue">specialized knowledge</font> and expertise</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">strategy depends</font> in part     on our <font color="blue">continued ability</font> to develop and maintain <font color="blue"><font color="blue">relationship</font>s</font> with leading     academic and <font color="blue">research <font color="blue">institutions</font></font> and <font color="blue">with independent researchers</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">competition</font>  for  these  <font color="blue"><font color="blue">relationship</font>s</font>  is intense, and we can give no     assurances that we will be able to develop and maintain these <font color="blue"><font color="blue">relationship</font>s</font>     on acceptable terms</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________            We also seek <font color="blue">strategic alliances</font> with <font color="blue">corporate partners</font>, primarily     <font color="blue">pharmaceutical</font>  and  <font color="blue">bio<font color="blue">technology</font></font>  companies,  to help us develop and     <font color="blue">commercialize</font> drugs</td>
    </tr>
    <tr>
      <td>Various problems can arise in <font color="blue">strategic alliances</font></td>
    </tr>
    <tr>
      <td>A     <font color="blue">partner responsible</font> for <font color="blue">conducting <font color="blue"><font color="blue">clinical trial</font>s</font></font> and obtaining <font color="blue">regulatory</font>     <font color="blue">approval may fail</font> to develop a <font color="blue">marketable drug</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">partner may decide</font> to     pursue an <font color="blue">alternative strategy</font> or focus its <font color="blue">efforts on alliances</font> or other     <font color="blue"><font color="blue">arrangements</font> with</font> <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>A partner that has <font color="blue">been granted marketing</font>     rights for a <font color="blue">certain drug within</font> a <font color="blue">geographic area may fail</font> to market the     <font color="blue">drug <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Consequently, <font color="blue">strategic alliances</font> that we may <font color="blue">enter into</font>     may not be <font color="blue">scientifically</font> or <font color="blue">commercially successful</font></td>
    </tr>
    <tr>
      <td>In this regard, in     April  2002,  we  entered  into a series of <font color="blue">agreement</font>s relating to the     <font color="blue">development</font>  and  <font color="blue">commercialization</font> of Genasense® with Aventis and its     <font color="blue">affiliates</font></td>
    </tr>
    <tr>
      <td>On May 10, 2005, we announced     that we and Aventis had signed an <font color="blue">agreement</font> to terminate our <font color="blue">development</font> and     <font color="blue">commercialization</font> <font color="blue">collaboration</font> <font color="blue">for Genasense</font>® as described above</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the resources that any <font color="blue"><font color="blue">collaborator</font> may devote</font> to our     products</td>
    </tr>
    <tr>
      <td>Any of our present or future <font color="blue"><font color="blue">collaborator</font>s</font> may not perform their     <font color="blue">obligations</font> as expected</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">collaborator</font>s</font> may breach or terminate their     <font color="blue">agreement</font>s with us, for <font color="blue">instance upon</font> changes in control or <font color="blue">management</font> of     the <font color="blue">collaborator</font>, or they <font color="blue">may otherwise fail</font> to conduct their <font color="blue">collaborative</font>     <font color="blue"><font color="blue">activities</font> <font color="blue">successfully</font></font> and in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>In  addition, our <font color="blue"><font color="blue">collaborator</font>s</font> may elect not to develop products     arising  out of our <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font></font> or to <font color="blue">devote sufficient</font>     resources to the <font color="blue">development</font>, <font color="blue">regulatory</font> approval, <font color="blue">manufacture</font>, marketing or     sale of these products</td>
    </tr>
    <tr>
      <td>If any of these events occur, we may not be able to     develop our products or <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>An important part of our <font color="blue">strategy involves conducting multiple product</font>     <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We <font color="blue">may pursue opportunities</font> in fields that conflict     with  those  of our <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, dis<font color="blue">agreement</font>s with our     <font color="blue"><font color="blue">collaborator</font>s</font> could develop <font color="blue">over rights</font> to our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>The     resolution of <font color="blue">such conflicts</font> and dis<font color="blue">agreement</font>s may require us to <font color="blue">relinquish</font>     rights to our <font color="blue">intellectual property</font> that we believe we are entitled to</td>
    </tr>
    <tr>
      <td>In     addition, any dis<font color="blue">agreement</font> or <font color="blue">conflict with</font> our <font color="blue"><font color="blue">collaborator</font>s</font> could reduce     our ability to obtain future <font color="blue">collaboration</font> <font color="blue">agreement</font>s and <font color="blue">negatively impact</font>     our  <font color="blue">relationship</font>  with  existing  <font color="blue"><font color="blue">collaborator</font>s</font></td>
    </tr>
    <tr>
      <td>Such  a conflict or     dis<font color="blue">agreement</font>  could  also  lead  to  delays in <font color="blue">collaborative</font> research,     <font color="blue">development</font>, <font color="blue">regulatory</font> approval or <font color="blue">commercialization</font> of various products or     could require or result in <font color="blue">litigation</font> or <font color="blue">arbitration</font>, which would be time     consuming and expensive, divert the attention of our <font color="blue">management</font> and could     have a <font color="blue">significant</font> negative impact on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We anticipate that we <font color="blue">will <font color="blue">incur <font color="blue">additional</font></font> losses</font> and we may never be     profitable</td>
    </tr>
    <tr>
      <td>We have <font color="blue">never been profitable</font></td>
    </tr>
    <tr>
      <td>We have incurred substantial annual     operating  losses  associated  with  ongoing  research and <font color="blue">development</font>     <font color="blue">activities</font>, pre<font color="blue">clinical testing</font>, <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">regulatory</font> <font color="blue">submissions</font> and     <font color="blue">manufacturing <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>From the period since our inception to <font color="blue">December </font>    31, 2005, we have incurred a <font color="blue">cumulative net loss</font> of dlra358dtta2 million</td>
    </tr>
    <tr>
      <td>We may     never achieve <font color="blue">revenue sufficient</font> for us to <font color="blue">attain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Achieving     </font><font color="blue">profitability</font> is <font color="blue">unlikely unless</font> Genasense® receives <font color="blue">approval from</font> the FDA     for commercial sale in one or more <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends heavily on</font> a small number of products</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently market</font> and <font color="blue">sell one product</font>, Ganite® and the principal     <font color="blue">patent covering</font> its use for the <font color="blue">approved <font color="blue">indication</font> expired</font> in April 2005</td>
    </tr>
    <tr>
      <td>We do not expect to expand our marketed product portfolio <font color="blue"><font color="blue">significant</font>ly</font> in     the short <font color="blue">term unless</font> Genasense® receives <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>If Genasense®     is not approved, if approval is <font color="blue"><font color="blue">significant</font>ly</font> delayed, or if in the event of     approval,  the  product is commercially <font color="blue">unsuccessful</font>, we do not expect     <font color="blue">significant</font>  sales  of other products to offset this loss of potential     revenue</td>
    </tr>
    <tr>
      <td>To diversify our <font color="blue">product line</font> in the long term, it will be important     for us to identify suitable <font color="blue">technologies</font> and products for <font color="blue">acquisition</font> or     licensing  and  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable to identify suitable     <font color="blue">technologies</font>  and  products, or if we are unable to acquire or license     products we identify, we may be unable to diversify our <font color="blue">product line</font> and to     generate long-term growth</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________           We may be unable to obtain or <font color="blue">enforce patents</font>, other <font color="blue">proprietary rights</font> and     licenses to protect our business; we could become involved in <font color="blue">litigation</font>     relating to our patents or licenses that could cause us to <font color="blue">incur <font color="blue">additional</font></font>     costs and delay or prevent our <font color="blue">introduction</font> of new drugs to market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> to a large extent on our ability to:       o   obtain US and foreign patent or other <font color="blue">proprietary protection</font> for our     <font color="blue">technologies</font>, products and processes;       o   <font color="blue">preserve trade secrets</font>; and       o   operate <font color="blue">without infringing</font> the patent and other <font color="blue">proprietary rights</font> of     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Legal  standards  relating  to  the  validity of <font color="blue">patents cover</font>ing     <font color="blue">pharmaceutical</font> and <font color="blue">biotechnological <font color="blue">inventions</font></font> and the scope of claims made     under these types of patents are still developing, and they <font color="blue">involve complex</font>     legal and factual questions</td>
    </tr>
    <tr>
      <td>If we are unable to     obtain and <font color="blue">enforce patents</font> and licenses to protect our drugs, our business,     results of <font color="blue">operations</font> and <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We hold numerous US, foreign and <font color="blue">international <font color="blue">patents cover</font>ing</font>     <font color="blue">various aspects</font> of our <font color="blue">technology</font>, which include <font color="blue">novel compositions</font> of     matter, methods of large-scale synthesis and methods of <font color="blue">controlling gene</font>     expression and methods of <font color="blue">treating disease</font></td>
    </tr>
    <tr>
      <td>In the future, however, we may     not be successful in obtaining <font color="blue">additional</font> patents despite pending or future     <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Moreover, our current and <font color="blue">future <font color="blue">patents may</font></font> not be sufficient     to protect us against <font color="blue">competitors</font> who use similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Additionally,     our patents, the patents of our business partners and the patents for which     we have obtained <font color="blue">licensing rights may</font> be challenged, narrowed, invalidated     or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">rights <font color="blue">granted under</font></font> our <font color="blue">patents may</font> not be     <font color="blue">broad enough</font> to <font color="blue">cover commercially</font> valuable drugs or processes and therefore     may  not <font color="blue">provide us with</font> sufficient competitive advantage with respect     thereto</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> industries have <font color="blue">been greatly</font>     affected by time-consuming and expensive <font color="blue">litigation</font> regarding patents and     other <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>We may be required to commence, or may     be made a party to, <font color="blue">litigation</font> relating to the scope and validity of our     <font color="blue">intellectual property</font> rights or the <font color="blue">intellectual property</font> rights of others</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">litigation</font>  could  result  in  adverse  <font color="blue">decisions</font>  regarding the     <font color="blue">patentability</font> of our <font color="blue">inventions</font> and products, the enforceability, validity     or scope of <font color="blue">protection offered by</font> our patents or our <font color="blue">infringement</font> of patents     held by others</td>
    </tr>
    <tr>
      <td>Such <font color="blue">decisions</font> could make us liable for substantial money     damages,  or <font color="blue">could bar us from</font> the <font color="blue">manufacture</font>, sale or use of certain     products</td>
    </tr>
    <tr>
      <td>The costs of any <font color="blue">license may</font> be <font color="blue">prohibitive</font> and we may     not  be able to <font color="blue">enter into</font> any required <font color="blue">licensing arrangement on terms</font>     acceptable to us</td>
    </tr>
    <tr>
      <td>The cost to us of any <font color="blue">litigation</font> or proceeding relating to patent or     license rights, even if resolved in our favor, could be substantial</td>
    </tr>
    <tr>
      <td>Some of     our  <font color="blue">competitors</font> may be able to sustain the costs of complex patent or     licensing  <font color="blue">litigation</font>  more  <font color="blue"><font color="blue">effective</font>ly</font>  than we can because of their     <font color="blue">substantially</font> greater resources</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>resulting from the <font color="blue">initiation</font>     and <font color="blue">continuation</font> of any patent or related <font color="blue">litigation</font> could have a material     adverse effect on our ability to compete in the marketplace</td>
    </tr>
    <tr>
      <td>We also may be required to <font color="blue">participate</font> in <font color="blue">interference <font color="blue">proceedings</font></font>     declared by the <font color="blue">US Patent and Trademark Office </font>in opposition or similar     <font color="blue">proceedings</font>  before  foreign patent offices and in International Trade     Commission <font color="blue">proceedings</font> aimed at preventing the <font color="blue">importation</font> of drugs that     <font color="blue">would compete unfairly with</font> our drugs</td>
    </tr>
    <tr>
      <td>These types of <font color="blue">proceedings</font> could     cause us to incur considerable costs</td>
    </tr>
    <tr>
      <td>The principal <font color="blue">patent covering</font> the use of Ganite® for its approved     <font color="blue">indication</font> expired, including Hatch-Waxman <font color="blue">extensions</font>, in April 2005</td>
    </tr>
    <tr>
      <td>We have licensed a portfolio of US patents and <font color="blue">application</font>s from the     University  of Pennsylvania and the NIH relating to Genasense® and its     backbone <font color="blue">chemistry</font> that expire between 2008 and 2015</td>
    </tr>
    <tr>
      <td><font color="blue">Corresponding </font>patent     <font color="blue">application</font>s have been filed in Canada, Europe and Japan</td>
    </tr>
    <tr>
      <td>The claims of     these <font color="blue">patents cover</font> our <font color="blue">proprietary antisense <font color="blue">oligonucleotide</font> molecules</font>     <font color="blue">which target</font> the Bcl-2 mRNA and <font color="blue">methods employing them</font></td>
    </tr>
    <tr>
      <td>We also hold several     US patent <font color="blue">application</font>s relating to methods of using Genasense® that expire     in 2020, with approximately 45 corresponding foreign patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________           Most of our products are in an <font color="blue">early stage</font> of <font color="blue">development</font>, and we may never     receive <font color="blue">regulatory</font> approval for these products</td>
    </tr>
    <tr>
      <td>Most  of  our  resources  have been dedicated to the research and     <font color="blue">development</font>  of  potential  antisense  <font color="blue">pharmaceutical</font> <font color="blue">products such as</font>     Genasense®,  based  upon  <font color="blue">oligonucleotide</font>  <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>While  we have     <font color="blue">demonstrate</font>d the activity of antisense <font color="blue">oligonucleotide</font> <font color="blue">technology</font> in model     systems in vitro and in animals, Genasense® is our <font color="blue">only antisense product</font> to     have <font color="blue">been tested</font> in humans</td>
    </tr>
    <tr>
      <td>Several of our other <font color="blue">technologies</font> that serve as     a  possible  basis for <font color="blue">pharmaceutical</font> products are only in preclinical     testing</td>
    </tr>
    <tr>
      <td><font color="blue">Results  </font>obtained  in  <font color="blue">preclinical studies</font> or <font color="blue">early clinical</font>     <font color="blue">investigations</font>  are not <font color="blue">necessarily indicative</font> of results that will be     obtained in <font color="blue">extended human <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may prove</font> to have     undesirable and unintended side effects or other <font color="blue">characteristics</font> that may     prevent our obtaining FDA or foreign <font color="blue">regulatory</font> approval for any <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>In addition, it is possible that research and <font color="blue">discoveries by others will</font>     render our <font color="blue">oligonucleotide</font> <font color="blue">technology</font> obsolete or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>We will not be able to <font color="blue">commercialize</font> our <font color="blue"><font color="blue">product candidate</font>s</font> if our     <font color="blue">preclinical studies</font> do not produce successful results or if our clinical     trials do not <font color="blue">demonstrate</font> safety and efficacy in humans</td>
    </tr>
    <tr>
      <td>Our  success  <font color="blue">will depend on</font> the success of our <font color="blue">currently ongoing</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> and subsequent <font color="blue"><font color="blue">clinical trial</font>s</font> that have not yet begun</td>
    </tr>
    <tr>
      <td>It     may take <font color="blue">several years</font> to complete the <font color="blue"><font color="blue">clinical trial</font>s</font> of a product, and a     failure of one or more of our <font color="blue"><font color="blue">clinical trial</font>s</font> can occur at any stage of     testing</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">development</font> of each of our <font color="blue"><font color="blue">product candidate</font>s</font>     involves <font color="blue">significant</font> risks at each stage of testing</td>
    </tr>
    <tr>
      <td>If <font color="blue">clinical trial</font>     <font color="blue">difficult</font>ies  and  failures arise, our <font color="blue"><font color="blue">product candidate</font>s</font> may never be     approved for sale or <font color="blue">become commercially viable</font></td>
    </tr>
    <tr>
      <td>We do not believe that any     of our <font color="blue"><font color="blue">product candidate</font>s</font> have <font color="blue">alternative uses</font> if our current <font color="blue">development</font>     <font color="blue">activities</font> are <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>There are a number of <font color="blue">difficult</font>ies and <font color="blue">risks associated with clinical</font>     trials</td>
    </tr>
    <tr>
      <td>These <font color="blue">difficult</font>ies and risks may result in the failure to receive     <font color="blue">regulatory</font> approval to sell our <font color="blue"><font color="blue">product candidate</font>s</font> or the <font color="blue">inability</font> to     <font color="blue">commercialize</font> any of our <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">possibility</font> exists that:            ·  we  may discover that a <font color="blue">product candidate</font> does not exhibit the     expected <font color="blue">therapeutic</font> results in humans, may cause harmful side effects or     have other unexpected <font color="blue">characteristics</font> that may delay or preclude <font color="blue">regulatory</font>     approval or <font color="blue">limit commercial use</font> if approved;            · the results from <font color="blue">early clinical</font> trials may not be <font color="blue">statistically</font>     <font color="blue">significant</font> or predictive of results that will be obtained <font color="blue">from expanded</font>,     advanced <font color="blue"><font color="blue">clinical trial</font>s</font>;            · <font color="blue">institutional review boards</font> or <font color="blue">regulators</font>, including the FDA, may     hold, suspend or terminate our <font color="blue">clinical research</font> or the <font color="blue"><font color="blue">clinical trial</font>s</font> of     our <font color="blue"><font color="blue">product candidate</font>s</font> for <font color="blue">various reasons</font>, including <font color="blue">noncompliance with</font>     <font color="blue">regulatory</font> <font color="blue">requirement</font>s or if, in their opinion, the <font color="blue">participating subjects</font>     are being exposed to unacceptable <font color="blue">health risks</font>;            · <font color="blue">subjects may drop out</font> of our <font color="blue"><font color="blue">clinical trial</font>s</font>;            · our <font color="blue">preclinical studies</font> or <font color="blue"><font color="blue">clinical trial</font>s</font> may produce negative,     <font color="blue">inconsistent</font> or <font color="blue">inconclusive</font> results, and we may decide, or <font color="blue">regulators</font> may     require us, to conduct <font color="blue">additional</font> <font color="blue">preclinical studies</font> or <font color="blue"><font color="blue">clinical trial</font>s</font>;     and            · the cost of our <font color="blue"><font color="blue">clinical trial</font>s</font> may be <font color="blue">greater than</font> we currently     anticipate</td>
    </tr>
    <tr>
      <td>For example, in November 2004, we reported that our randomized Phase 3     <font color="blue">clinical trial</font> of Genasense® in <font color="blue">patients with</font> multiple myeloma did not meet     its <font color="blue">primary endpoint</font></td>
    </tr>
    <tr>
      <td>The trial had <font color="blue">been designed</font> to <font color="blue">evaluate whether</font> the     addition of Genasense® to standard therapy with high-dose <font color="blue">dexamethasone</font>     could increase the time to <font color="blue">development</font> of <font color="blue">progressive</font> disease in patients     who <font color="blue">previously</font> had received extensive therapy</td>
    </tr>
    <tr>
      <td>Based on the results of the     Phase 3 trial, we have no plans to submit an NDA in this <font color="blue">indication</font> to the     FDA at the current time</td>
    </tr>
    <tr>
      <td>We have not yet determined what <font color="blue">additional</font> clinical     trials, if any, may be undertaken in <font color="blue">patients with</font> multiple myeloma</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________            We <font color="blue">cannot assure</font> you that our ongoing <font color="blue">preclinical studies</font> and clinical     trials  will produce successful results in order to support <font color="blue">regulatory</font>     approval of Genasense® in any territory or for any <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Failure to     obtain approval, or a substantial delay in approval of Genasense® for these     or any other <font color="blue"><font color="blue">indication</font>s</font> would have a material adverse effect on our results     of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Clinical trials are costly and time consuming and are subject to delays; our     business <font color="blue">would suffer</font> if the <font color="blue">development</font> process relating to our products     were subject to <font color="blue">meaningful delays</font></td>
    </tr>
    <tr>
      <td>Clinical trials are very costly and time-consuming</td>
    </tr>
    <tr>
      <td>The length of time     required to complete a <font color="blue">clinical study</font> depends upon many factors, including     but  not limited to the size of the <font color="blue">patient population</font>, the ability of     patients  to  get  to the site of the <font color="blue">clinical study</font>, the criteria for     determining <font color="blue">which patients</font> are eligible to join the study and other issues</td>
    </tr>
    <tr>
      <td>Delays in patient <font color="blue">enrollment</font> and other unforeseen <font color="blue">development</font>s could delay     <font color="blue">completion</font> of a <font color="blue">clinical study</font> and increase its costs, which could also     delay any <font color="blue">eventual commercial sale</font> of the drug that is the subject of the     <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commencement</font> and rate of <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> also may be     <font color="blue">delayed by</font> many other factors, including the following:       o   <font color="blue">inability</font> to obtain <font color="blue">sufficient quantities</font> of materials for use in     <font color="blue"><font color="blue">clinical trial</font>s</font>;       o   <font color="blue">inability</font> to <font color="blue">adequately monitor patient</font> progress after treatment;       o   <font color="blue">unforeseen safety issues</font>;       o   the failure of the products to perform well during <font color="blue"><font color="blue">clinical trial</font>s</font> and       o   <font color="blue">government</font> or <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>If we fail to obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals, we <font color="blue">cannot market</font>     and sell our products in the <font color="blue">United States</font> or in other countries</td>
    </tr>
    <tr>
      <td>The FDA and comparable <font color="blue">regulatory</font> agencies in <font color="blue">foreign countries</font> (such     as the EMEA) impose substantial pre-market approval <font color="blue">requirement</font>s on the     <font color="blue">introduction</font> of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>These <font color="blue">requirement</font>s involve lengthy     and  detailed  preclinical  and  <font color="blue">clinical testing</font> and other costly and     time-consuming procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of these <font color="blue">requirement</font>s typically     takes <font color="blue">several years</font> or more depending upon the type, <font color="blue">complexity</font> and novelty     of  the product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot apply</font> for FDA approval to market any of our     products under <font color="blue">development</font> until preclinical and <font color="blue"><font color="blue">clinical trial</font>s</font> on the     product are <font color="blue">successfully</font> completed</td>
    </tr>
    <tr>
      <td>Several <font color="blue">factors could</font> prevent successful     <font color="blue">completion</font>  or  cause <font color="blue">significant</font> delays of these trials, including an     <font color="blue">inability</font>  to  enroll  the  required  number of patients or failure to     <font color="blue">demonstrate</font> adequately that the product is safe and <font color="blue">effective</font> for use in     humans</td>
    </tr>
    <tr>
      <td>If <font color="blue">safety concerns</font> develop, the FDA <font color="blue">could stop</font> our trials before     <font color="blue">completion</font></td>
    </tr>
    <tr>
      <td>We may not market or sell any product for which we have not     obtained <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>In May 2004, the <font color="blue">application</font> failed to gain a     majority  vote  for marketing <font color="blue">approval from</font> ODAC As a consequence, we     withdrew the NDA, <font color="blue">which allows us</font> to <font color="blue">potentially resubmit</font> the <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>We  cannot  assure you that the FDA, <font color="blue">the EMEA </font>or other <font color="blue">regulatory</font>     agencies  will  ever  approve  the  use of our products that are under     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">patient population</font>s for which our products are approved     are not <font color="blue">sufficiently</font> broad, or if approval is <font color="blue">accompanied</font> by <font color="blue">unanticipated</font>     labeling <font color="blue">restrictions</font>, the <font color="blue">commercial success</font> of our products could be     limited and our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font>     could <font color="blue">consequently</font> be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>If the third party <font color="blue"><font color="blue">manufacture</font>rs</font> upon which we rely fail to produce our     products in the volumes that we require on a <font color="blue">timely basis</font>, or to <font color="blue">comply with</font>     <font color="blue">stringent <font color="blue">regulations</font> applicable</font> to <font color="blue">pharmaceutical</font> drug <font color="blue"><font color="blue">manufacture</font>rs</font>, we     <font color="blue">may face delays</font> in the <font color="blue">commercialization</font> of, or be unable to meet demand     for, our products and <font color="blue">may lose <font color="blue">potential revenues</font></font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">manufacture</font> any of our products or <font color="blue"><font color="blue">product candidate</font>s</font> and we     do  not plan to develop any <font color="blue">capacity</font> to do so</td>
    </tr>
    <tr>
      <td>We have <font color="blue">contracted with</font>     third-party  <font color="blue"><font color="blue">manufacture</font>rs</font>  to <font color="blue">manufacture</font> Ganite® and Genasense®</td>
    </tr>
    <tr>
      <td>The     <font color="blue">manufacture</font> of <font color="blue">pharmaceutical</font> products requires <font color="blue">significant</font> expertise and     capital <font color="blue">investment</font>, including the <font color="blue">development</font> of <font color="blue">advanced manufacturing</font>     <font color="blue">techniques</font> and <font color="blue">process controls</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of <font color="blue">pharmaceutical</font> products     often encounter <font color="blue">difficult</font>ies in production, <font color="blue">especially</font> in scaling up initial     production</td>
    </tr>
    <tr>
      <td>These problems include <font color="blue">difficult</font>ies with production costs and     yields, quality control and assurance and shortages of <font color="blue">qualified personnel</font>,     <font color="blue">as well as compliance with strictly enforced federal</font>, state and foreign     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> may not perform as agreed or may     terminate their <font color="blue">agreement</font>s with us</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________            In addition to <font color="blue">product approval</font>, any <font color="blue">facility</font> in which Genasense® is     <font color="blue">manufacture</font>d or tested for its ability to meet required <font color="blue">specifications must</font>     be <font color="blue">approved by</font> the FDA and/or <font color="blue">the EMEA </font>before it can <font color="blue">manufacture</font> Genasense®</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>of  the  <font color="blue">facility</font>  to be approved could delay the approval of     Genasense®</td>
    </tr>
    <tr>
      <td>We do not currently have <font color="blue">alternate manufacturing</font> plans in place</td>
    </tr>
    <tr>
      <td>The     number of third-party <font color="blue"><font color="blue">manufacture</font>rs</font> with the expertise, required <font color="blue">regulatory</font>     approvals and <font color="blue">facilities</font> to <font color="blue">manufacture</font> bulk drug substance on a commercial     scale is limited, and it would take a <font color="blue">significant</font> amount of time to arrange     for alternative <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>If we need to change to other commercial     <font color="blue"><font color="blue">manufacture</font>rs</font>, the FDA and comparable foreign <font color="blue">regulators</font> must approve these     <font color="blue"><font color="blue">manufacture</font>rs</font>’  <font color="blue">facilities</font> and processes prior to our use, which would     require new testing and compliance <font color="blue">inspections</font>, and the new <font color="blue"><font color="blue">manufacture</font>rs</font>     would  have  to  be educated in or <font color="blue">independently</font> develop the processes     <font color="blue">necessary</font> for the production of our products</td>
    </tr>
    <tr>
      <td>Any  of these <font color="blue">factors could</font> cause us to delay or suspend clinical     trials, <font color="blue">regulatory</font> <font color="blue">submissions</font>, required approvals or <font color="blue">commercialization</font> of     our products or <font color="blue"><font color="blue">product candidate</font>s</font>, entail higher costs and result in our     being unable to <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Furthermore, if our     third-party <font color="blue"><font color="blue">manufacture</font>rs</font> fail to deliver the required <font color="blue">commercial quantities</font>     of  bulk  drug  substance or finished <font color="blue">product on</font> a <font color="blue">timely basis</font> and at     <font color="blue">commercially reasonable prices</font>, and we were unable to <font color="blue">promptly find one</font> or     more replacement <font color="blue"><font color="blue">manufacture</font>rs</font> capable of <font color="blue">production at</font> a <font color="blue">substantially</font>     <font color="blue">equivalent cost</font>, in <font color="blue">substantially</font> equivalent volume and on a <font color="blue">timely basis</font>,     we <font color="blue">would likely</font> be unable to meet demand for our products and we would lose     <font color="blue">potential revenues</font></td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">regulatory</font> approval, we will be subject to ongoing     regulation, and any <font color="blue">failure by us</font> or our <font color="blue"><font color="blue">manufacture</font>rs</font> to <font color="blue">comply with</font> such     <font color="blue">regulation could suspend</font> or eliminate our ability to sell our products</td>
    </tr>
    <tr>
      <td>Ganite®, Genasense®, if it obtains <font color="blue">regulatory</font> approval, and any other     product we may develop will be subject to ongoing <font color="blue">regulatory</font> oversight,     <font color="blue">primarily by</font> the FDA Failure to <font color="blue">comply with</font> post-marketing <font color="blue">requirement</font>s,     such as maintenance by us or by the <font color="blue"><font color="blue">manufacture</font>rs</font> of our products of current     <font color="blue">Good Manufacturing Practices </font>as required by the FDA, or safety surveillance     of such products or lack of compliance with other <font color="blue">regulations</font> could result     in suspension or <font color="blue">limitation</font> of approvals or other <font color="blue">enforcement actions</font></td>
    </tr>
    <tr>
      <td>Current <font color="blue">Good Manufacturing Practices </font>are FDA <font color="blue">regulations</font> that define the     minimum  standards  that  must  be  met  by companies that <font color="blue">manufacture</font>     <font color="blue">pharmaceutical</font>s and apply to all drugs for human use including those to be     used in <font color="blue"><font color="blue">clinical trial</font>s</font> as well as those produced for <font color="blue">general sale</font> after     approval of an <font color="blue">application</font> by the FDA These <font color="blue">regulations</font> define <font color="blue">requirement</font>s     for personnel, buildings and <font color="blue">facilities</font>, equipment, control of <font color="blue">raw materials</font>     and packaging components, production and <font color="blue">process controls</font>, packaging and     label  controls,  handling  and  <font color="blue">distribution</font>, laboratory controls and     <font color="blue">recordkeeping</font></td>
    </tr>
    <tr>
      <td>Furthermore, the terms of any <font color="blue">product candidate</font> approval,     including the <font color="blue">labeling content</font> and advertising <font color="blue">restrictions</font>, may be so     <font color="blue">restrictive</font>  that they could <font color="blue">adversely</font> affect the <font color="blue">marketability</font> of our     <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>Any such failure to comply or the <font color="blue">application</font> of such     <font color="blue">restrictions</font> could limit our ability to market our <font color="blue"><font color="blue">product candidate</font>s</font> and     may have a material adverse effect on our business, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Such failures or <font color="blue">restrictions</font> may also prompt     <font color="blue">regulatory</font> recalls of one or more of our products, which could have material     and <font color="blue">adverse effects on</font> our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">raw materials</font> for our products are produced by a limited number of     suppliers, and our business <font color="blue">could suffer</font> if we cannot obtain needed     <font color="blue">quantities at</font> acceptable prices and qualities</td>
    </tr>
    <tr>
      <td>The  raw  materials  that  we  require  to <font color="blue">manufacture</font> our drugs,     <font color="blue">particularly</font> <font color="blue">oligonucleotide</font>s, are <font color="blue">available from only</font> a <font color="blue">few suppliers</font></td>
    </tr>
    <tr>
      <td>If     these <font color="blue">suppliers cease</font> to <font color="blue">provide us with</font> the <font color="blue">necessary</font> <font color="blue">raw materials</font> or fail     to <font color="blue">provide us with</font> an <font color="blue">adequate supply</font> of <font color="blue">materials at</font> an acceptable price     and quality, we could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________           If third-party payors do not <font color="blue">provide coverage</font> and <font color="blue">reimbursement</font> for use of     our products, we may not be able to <font color="blue">successfully</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> drugs <font color="blue">successfully</font> will depend in part on     the extent to which various third-party payors are willing to reimburse     patients  for  the  costs  of  our drugs and related <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>third-party payors include <font color="blue">government</font> <font color="blue">authorities</font>, private health insurers     and  other  <font color="blue">organizations</font>,  such  as health maintenance <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payors often challenge</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font>     and services</td>
    </tr>
    <tr>
      <td>Accordingly, if <font color="blue">less costly drugs</font> are available, third-party     <font color="blue">payors may</font> not authorize or may limit <font color="blue">reimbursement</font> for our drugs, even if     they are safer or more <font color="blue">effective</font> than the <font color="blue">alternatives</font></td>
    </tr>
    <tr>
      <td>In addition, the     federal  <font color="blue">government</font>  and <font color="blue">private insurers</font> have changed and continue to     consider  ways  to change the manner in <font color="blue">which health care products</font> and     services are provided and paid for in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In particular,     these third-party payors are <font color="blue">increasingly attempting</font> to <font color="blue">contain health care</font>     <font color="blue">costs by limiting both coverage</font> and the level of <font color="blue">reimbursement</font> for new     <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>In the future, it is possible that the <font color="blue">government</font> may     institute  price  controls and further limits on <font color="blue">Medicare and Medicaid     </font>spending</td>
    </tr>
    <tr>
      <td>These controls and <font color="blue">limits could affect</font> the payments we collect     from sales of our products</td>
    </tr>
    <tr>
      <td>Internationally, medical <font color="blue">reimbursement</font> systems     vary <font color="blue"><font color="blue">significant</font>ly</font>, with some countries requiring <font color="blue">application</font> for, and     approval of, <font color="blue">government</font> or third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In addition, some     <font color="blue">medical centers</font> in <font color="blue">foreign countries</font> have fixed budgets, regardless of     levels of <font color="blue">patient care</font></td>
    </tr>
    <tr>
      <td>Even if we succeed in bringing <font color="blue">therapeutic</font> products     to market, uncertainties regarding future health care policy, legislation     and  regulation, as well as private market practices, could affect our     ability to sell our products in quantities, or at prices, that will enable     us to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to <font color="blue"><font color="blue">potential product</font> <font color="blue">liability</font></font> that may have a     negative effect on our <font color="blue">financial performance</font> and our business <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">administration</font> of drugs to humans, whether in <font color="blue"><font color="blue">clinical trial</font>s</font> or     commercially, <font color="blue">exposes us</font> to <font color="blue">potential product</font> and <font color="blue">professional <font color="blue">liability</font></font>     risks, which are inherent in the testing, production, marketing and sale of     human <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims can be expensive to     defend and may result in large judgments or settlements <font color="blue">against us</font>, which     could have a negative effect on our <font color="blue">financial performance</font> and <font color="blue">materially</font> and     <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>We maintain product <font color="blue">liability</font> insurance     (subject to various deductibles), but our <font color="blue">insurance coverage may</font> not be     sufficient to cover claims</td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be certain that we will     always  be  able  to maintain or increase our <font color="blue">insurance coverage at</font> an     <font color="blue">affordable price</font></td>
    </tr>
    <tr>
      <td>Even if a product <font color="blue">liability</font> claim is not successful, the     adverse  publicity  and time and expense of <font color="blue">defending such</font> a claim may     <font color="blue">interfere with</font> or <font color="blue">adversely</font> affect our business and <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>We may incur a variety of costs to engage in future <font color="blue">acquisition</font>s of     companies, products or <font color="blue">technologies</font>, and the anticipated benefits of those     <font color="blue">acquisition</font>s may never be realized</td>
    </tr>
    <tr>
      <td>As a part of our business strategy, we may make <font color="blue">acquisition</font>s of, or     <font color="blue">significant</font>  <font color="blue">investment</font>s  in,  <font color="blue">complementary</font>  companies,  products  or     <font color="blue">technologies</font>,  although  no <font color="blue">significant</font> <font color="blue">acquisition</font> or <font color="blue">investment</font>s are     <font color="blue">currently pending</font></td>
    </tr>
    <tr>
      <td>Any future <font color="blue">acquisition</font>s would be <font color="blue">accompanied</font> by risks     such as:       o   <font color="blue">difficult</font>ies in <font color="blue">assimilating</font> the <font color="blue">operations</font> and personnel of acquired     companies;       o   diversion of our <font color="blue">management</font>’s attention from ongoing business concerns;       o   our potential <font color="blue">inability</font> to maximize our financial and <font color="blue">strategic position</font>     through the <font color="blue">successful <font color="blue">incorporation</font></font> of acquired <font color="blue">technology</font> and <font color="blue">rights into</font>     our products and services;       o   <font color="blue">additional</font> expense associated with amortization of acquired assets;       o   maintenance of uniform standards, controls, procedures and policies; and       o   <font color="blue">impairment</font> of existing <font color="blue"><font color="blue">relationship</font>s</font> with employees, suppliers and     <font color="blue">customers as</font> a result of the <font color="blue">integration</font> of new <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________            We <font color="blue">cannot guarantee</font> that we will be able to <font color="blue">successfully</font> integrate any     business, products, <font color="blue">technologies</font> or personnel that we might acquire in the     future, and our failure to do so <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>We face substantial <font color="blue">competition</font> from other companies and research     <font color="blue">institutions</font> that are developing similar products, and we may not be able to     compete <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>In many cases, our products under <font color="blue">development</font> will be <font color="blue">competing with</font>     <font color="blue">existing therapies</font> for market share</td>
    </tr>
    <tr>
      <td>In addition, a number of companies are     pursuing the <font color="blue">development</font> of antisense <font color="blue">technology</font> and controlled-release     formulation <font color="blue">technology</font> and the <font color="blue">development</font> of <font color="blue">pharmaceutical</font>s utilizing such     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We compete with fully integrated <font color="blue">pharmaceutical</font> companies that     have more substantial experience, financial and other resources and superior     expertise in research and <font color="blue">development</font>, manufacturing, testing, obtaining     <font color="blue">regulatory</font> approvals, marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Smaller <font color="blue">companies may also</font>     prove  to  be  <font color="blue">significant</font>  <font color="blue">competitors</font>,  <font color="blue">particularly</font>  through  their     <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangements</font> with</font> large <font color="blue">pharmaceutical</font> companies or academic     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Furthermore, academic <font color="blue">institutions</font>, <font color="blue">government</font>al agencies and     other public and private research <font color="blue">organizations</font> have conducted and will     continue  to  conduct  research,  <font color="blue">seek <font color="blue">patent protection</font></font> and establish     <font color="blue">arrangements</font>  for  <font color="blue">commercializing</font> products</td>
    </tr>
    <tr>
      <td>Such products may compete     <font color="blue">directly with</font> any products that may be <font color="blue">offered by us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competition</font> will be determined in part by the potential <font color="blue"><font color="blue">indication</font>s</font>     for which our products are developed and ultimately <font color="blue">approved by</font> <font color="blue">regulatory</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>For certain of our <font color="blue">potential product</font>s, an important factor in     <font color="blue">competition</font>  may  be  the  timing of market <font color="blue">introduction</font> of our or our     <font color="blue">competitors</font>’ products</td>
    </tr>
    <tr>
      <td>Accordingly, the relative speed with which we can     develop products, complete the <font color="blue"><font color="blue">clinical trial</font>s</font> and approval processes and     supply <font color="blue">commercial quantities</font> of the products to the market are expected to     be <font color="blue">important competitive factors</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">competition</font> among products     approved for sale will be based, among other things, on product efficacy,     safety,  re<font color="blue">liability</font>,  <font color="blue">availability</font>, price, patent position and sales,     marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> by others of new     treatment   methods   could  render  our  products  under  <font color="blue">development</font>     non-competitive or obsolete</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitive position also depends upon</font> our ability to attract and     retain <font color="blue">qualified personnel</font>, obtain <font color="blue">patent protection</font> or otherwise develop     <font color="blue">proprietary products</font> or processes and <font color="blue">secure sufficient capital resources</font>     for  the often-substantial period between technological conception and     <font color="blue">commercial sales</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be successful in this     regard</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> our <font color="blue">key executives</font> and <font color="blue">scientists</font>, and the loss of key     personnel or the failure to attract <font color="blue">additional</font> <font color="blue">qualified personnel</font> could     harm our business</td>
    </tr>
    <tr>
      <td>Our business is highly <font color="blue">dependent on</font> our <font color="blue">key executives</font> and scientific     staff</td>
    </tr>
    <tr>
      <td>The  loss of <font color="blue">key personnel</font> or the failure to recruit <font color="blue">necessary</font>     <font color="blue">additional</font> or replacement personnel <font color="blue">will likely</font> impede the <font color="blue">achievement</font> of     our <font color="blue">development</font> objectives</td>
    </tr>
    <tr>
      <td>There is intense <font color="blue">competition</font> for qualified     personnel in the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> industries, and there can     be <font color="blue">no assurances</font> that we will be able to attract and retain the qualified     personnel <font color="blue">necessary</font> for the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>Risks Related to Outstanding Litigation           The outcome of and costs relating to <font color="blue">pending <font color="blue">shareholder</font></font> class action and     <font color="blue"><font color="blue">shareholder</font> derivative actions</font> are uncertain</td>
    </tr>
    <tr>
      <td>In 2004, numerous <font color="blue">complaints</font> were filed in the <font color="blue">United States</font> District     Court for the District of <font color="blue">New Jersey </font><font color="blue">against us</font> and certain of our principal     <font color="blue">officers on behalf</font> of <font color="blue">purported classes</font> of our <font color="blue"><font color="blue">shareholder</font>s</font> who purchased     our  <font color="blue">securities during several</font> class periods</td>
    </tr>
    <tr>
      <td>The <font color="blue">complaints</font> have been     <font color="blue">consolidated</font> into a <font color="blue">single action</font> and allege that we and certain of our     principal  officers  violated  the  <font color="blue">federal securities laws by issuing</font>     <font color="blue">materially</font> false and <font color="blue">misleading statements</font> regarding Genasense® for the     treatment  of  malignant  melanoma that had the effect of <font color="blue">artificially</font>     inflating the <font color="blue">market price</font> of our securities</td>
    </tr>
    <tr>
      <td>The <font color="blue">shareholder</font> class action     complaint in the <font color="blue">various actions seeks monetary damages</font> in an unspecified     amount and recovery of plaintiffs’ costs and attorneys’ fees</td>
    </tr>
    <tr>
      <td><font color="blue">On September     </font>30, 2005, the <font color="blue">court granted</font> in part and denied in part our motion to dismiss     the plaintiffs’ complaint</td>
    </tr>
    <tr>
      <td>The <font color="blue">court dismissed plaintiffs</font>’ claim that the     <font color="blue">defendants</font>  engaged in a scheme or artifice to defraud plaintiffs, but     <font color="blue">allowed plaintiffs</font>’ claims to <font color="blue">proceed with respect</font> to their <font color="blue">allegations</font> that     <font color="blue">defendants</font> issued false and <font color="blue">misleading public statements about</font> Genasense®</td>
    </tr>
    <tr>
      <td>If mediation is     <font color="blue">unsuccessful</font>, the case is expected to proceed to <font color="blue">discovery</font></td>
    </tr>
    <tr>
      <td>In addition, two separate <font color="blue"><font color="blue">shareholder</font> derivative actions</font> have been     <font color="blue">filed against</font> our <font color="blue">directors</font> and certain of our officers in <font color="blue"><font color="blue">New Jersey </font>State     </font>and  <font color="blue">Federal  </font>courts</td>
    </tr>
    <tr>
      <td>The  <font color="blue">Federal  </font><font color="blue">shareholder</font> derivative action was     <font color="blue">consolidated</font> with the <font color="blue">securities action</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Federal </font><font color="blue">derivative plaintiffs</font>     have not yet filed a <font color="blue">consolidated</font> amended complaint asserting their claims</td>
    </tr>
    <tr>
      <td>Instead, the Federal <font color="blue">shareholder</font> derivative action has been stayed, pending     <font color="blue">development</font>s in the Federal <font color="blue">securities action</font></td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________            Based  on  facts  <font color="blue">substantially</font>  similar to those asserted in the     <font color="blue">shareholder</font>  class actions, the state <font color="blue">derivative plaintiffs</font> claim that     <font color="blue">defendants</font> have breached their <font color="blue">fiduciary duties</font> to the <font color="blue"><font color="blue">shareholder</font>s</font> and     committed other violations of <font color="blue">New Jersey </font>law</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">February </font></font>9, 2006, the     Superior Court of <font color="blue">New Jersey </font>dismissed the plaintiffs &amp;apos  <font color="blue">derivative complaint</font>     in the <font color="blue">New Jersey </font>State case based in part <font color="blue">on plaintiffs failure</font> to make a     pre-suit demand on our <font color="blue">Board of Directors </font>and in part based on plaintiffs &amp;apos      failure  to  state  a  cause of action</td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font>served a motion for     <font color="blue">reconsideration on</font> <font color="blue">February </font>27, 2006</td>
    </tr>
    <tr>
      <td>We believe these <font color="blue">litigation</font>s are <font color="blue">without merit</font> and <font color="blue">will continue</font> to     <font color="blue">vigorously defend against</font> these suits</td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock           <font color="blue">Provisions </font>in our restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws and     <font color="blue">Delaware </font><font color="blue">law <font color="blue">may discourage</font></font> a takeover and prevent our <font color="blue"><font color="blue">stockholders</font> from</font>     receiving a premium for their shares</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws may     discourage  third  parties  from  seeking to obtain control of us and,     therefore, could prevent our <font color="blue"><font color="blue">stockholders</font> from</font> receiving a premium for their     shares</td>
    </tr>
    <tr>
      <td>Our  restated <font color="blue">certificate</font> of <font color="blue">incorporation</font> gives our board of     <font color="blue">directors</font> the power to <font color="blue">issue shares</font> of <font color="blue"><font color="blue">preferred stock</font> without approval</font> of     the holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">preferred stock</font> that is issued in the     <font color="blue">future could</font> have <font color="blue">voting rights</font>, including <font color="blue">voting rights</font> that could be     superior to that of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">affirmative vote</font> of 66-2/3prca of our     <font color="blue">voting stock</font> is required to <font color="blue">approve certain transactions</font> and to take certain     <font color="blue">stockholder actions</font>, including the <font color="blue">amendment</font> of <font color="blue">certain provisions</font> of our     <font color="blue">certificate</font> of <font color="blue">incorporation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">bylaws contain provisions</font> that regulate     how <font color="blue"><font color="blue">stockholders</font> may</font> present proposals or nominate <font color="blue">directors</font> for <font color="blue">election at</font>     <font color="blue">annual meetings</font> of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, we are subject to Section 203 of the <font color="blue">Delaware </font>General     Corporation  Law, which contains <font color="blue"><font color="blue">restrictions</font> on</font> stockholder action to     acquire control of us</td>
    </tr>
    <tr>
      <td>On  September  16, 2005, we announced that its <font color="blue">Board of Directors </font>    approved a <font color="blue">Stockholder Rights Plan </font>and declared a dividend of one preferred     stock purchase right (“Right”) for each share of our <font color="blue">common stock</font> held of     record as of the close of business on September 27, 2005</td>
    </tr>
    <tr>
      <td>In addition,     Rights shall be issued in respect of all shares of <font color="blue">common stock</font> issued after     such date, including the shares issued hereunder, pursuant to the Plan</td>
    </tr>
    <tr>
      <td>The     Rights  contain  provisions to protect <font color="blue">stockholders</font> in the event of an     <font color="blue">unsolicited attempt</font> to acquire us, including an <font color="blue">accumulation</font> of shares in     the <font color="blue">open market</font>, a partial or two-tier tender offer that does not treat all     <font color="blue">stockholders</font> equally and other <font color="blue">activities</font> that the Board believes are not in     the <font color="blue">best interests</font> of <font color="blue"><font color="blue">shareholder</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Rights </font><font color="blue">may discourage</font> a takeover and     prevent our <font color="blue"><font color="blue">stockholders</font> from</font> receiving a premium for their shares</td>
    </tr>
    <tr>
      <td>We have not paid, and do not expect to pay in the future, cash dividends on     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We  have <font color="blue">never paid cash dividends on</font> our <font color="blue">common stock</font> and do not     anticipate paying any <font color="blue">such dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We currently     intend to retain our earnings, if any, for the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font>, like that of the <font color="blue">common stock</font> of     many other bio<font color="blue">pharmaceutical</font> companies, has been and likely <font color="blue">will continue</font> to     be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Factors that could have a <font color="blue">significant</font> impact on the     <font color="blue">future price</font> of our <font color="blue">common stock</font> include but are not limited to:       o   the results of <font color="blue">preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> by us or our     <font color="blue">competitors</font>;       o   <font color="blue">announcements</font> of <font color="blue">technological innovations</font> or new <font color="blue">therapeutic</font> products     by us or our <font color="blue">competitors</font>;       o   <font color="blue">government</font> regulation;       o   <font color="blue">development</font>s in patent or other <font color="blue">proprietary rights</font> by us or our     respective <font color="blue">competitors</font>, including <font color="blue">litigation</font>;       o   <font color="blue">fluctuations</font> in our operating results; and       o   <font color="blue">market conditions</font> for bio<font color="blue">pharmaceutical</font> stocks in general</td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________            At <font color="blue">December </font>31, 2005, we had 114dtta5 million shares of <font color="blue">common stock</font>     outstanding, 11dtta0 million <font color="blue">additional</font> shares reserved for the <font color="blue">conversion</font> of     convertible <font color="blue">preferred stock</font> and the exercise of <font color="blue">outstanding options</font> and     warrants and 5dtta1 million <font color="blue">additional</font> shares of <font color="blue">common stock</font> authorized for     issuance and remaining to be <font color="blue">granted under</font> our <font color="blue">stock option</font> plans</td>
    </tr>
    <tr>
      <td><font color="blue">Future     </font>sales of shares of our <font color="blue">common stock</font> by existing <font color="blue">stockholders</font>, holders of     <font color="blue">preferred stock</font> who might convert such <font color="blue">preferred stock</font> into <font color="blue">common stock</font> and     option and <font color="blue">warrant holders</font> who <font color="blue">may exercise</font> their options and warrants to     purchase <font color="blue">common stock</font> also could <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Moreover, the <font color="blue">perception</font> that sales of substantial amounts of     our <font color="blue">common stock</font> might occur could <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>